RESEARCH PAPER

Advanced Glucose-Responsive Polymeric Microneedles: A Review of Stimuli-Sensitive Mechanisms, Fabrication Architectures, And Pharmacological Modulation of Metabolic Signaling

Partha Deb Roy[1], Vadivelan Ramachandran[2*], Kavi Bharathi Kumar[3]

[1] Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India

[2] Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India

[3] Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India

[*] Corresponding Author: Dr. Vadivelan Ramachandran, Professor & Head, Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
Email: vadivelanr@jssuni.edu.in

Received: 12th Mar, 2026 | **Revised:** 24th Mar, 2026 | **Accepted:** 14th Apr, 2026 | **Available Online:** 30th Apr, 2026

ABSTRACT

Diabetes mellitus remains one of the most prevalent and morbid chronic metabolic disorders globally, necessitating precise insulin delivery systems capable of dynamic, glucose-triggered responses. Conventional subcutaneous insulin administration fails to replicate the nuanced, on-demand secretion characteristic of pancreatic beta-cell physiology, culminating in hypoglycemic excursions, patient non-adherence, and long-term macrovascular sequelae. Glucose-responsive polymeric microneedles (GR-PMNs) have emerged as a transformative transdermal platform that integrates continuous glucose sensing with autonomous, closed-loop pharmacological release. This review systematically examines the molecular underpinnings of three principal stimuli-sensitive mechanisms — glucose oxidase-mediated pH and oxygen shifts, phenylboronic acid (PBA)-glucose reversible covalent binding, and lectin-mediated competitive displacement — as well as emerging enzyme-free concanavalin A and GLUT-inspired synthetic receptor strategies. Fabrication architectures including solid, hollow, coated, dissolving, and hydrogel microneedle arrays are analyzed with respect to skin penetration depth, drug payload capacity, biocompatibility, and manufacturability. The pharmacokinetic and pharmacodynamic consequences of microneedle-mediated dermal permeation — encompassing the epidermis-to-dermis gradient, lymphatic uptake, and transdermal bioavailability — are discussed in the context of insulin analogues, metformin, glucagon-like peptide-1 agonists, and emerging peptide mimetics. Preclinical and early-phase clinical evidence supporting GR-PMN efficacy in type 1 and type 2 diabetic models is critically appraised. Finally, regulatory, scalability, and patient-centric challenges are delineated alongside a forward-looking perspective on artificial intelligence-assisted patch design, microfluidic integration, and biodegradable next-generation formulations.

Keywords: glucose-responsive drug delivery; polymeric microneedles; phenylboronic acid; glucose oxidase; transdermal insulin; stimuli-sensitive polymers; closed-loop delivery; type 2 diabetes

How to cite this article: Roy PD, Ramachandran V, Kumar KB. Advanced Glucose-Responsive Polymeric Microneedles: A Review of Stimuli-Sensitive Mechanisms, Fabrication Architectures, And Pharmacological Modulation of Metabolic Signaling. Int J Drug Deliv Technol. 2026;16(5): 495-509. DOI: 10.25258/ijddt.16.5.53

Source of support: Nil.

Conflict of interest: None



Introduction

Diabetes mellitus affects over 537 million adults worldwide, a figure projected to escalate to 783 million by 2045 according to the International Diabetes Federation. (International Diabetes Federation, 2021) The pathophysiology of both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) converges upon inadequate glycemic regulation, with chronically elevated blood glucose concentrations driving the classic triad of microvascular, macrovascular, and neuropathic complications, including nephropathy, retinopathy, and cardiovascular disease. (American Diabetes Association, 2023) Exogenous insulin therapy, the cornerstone of T1DM management and an increasingly utilized adjunct in T2DM, demands meticulous dose calibration against real-time blood glucose levels, dietary intake, and physical activity — a burden that fuels suboptimal adherence and quality-of-life impairment. (Hirsch, 2005)

Conventional insulin delivery via subcutaneous hypodermic needles is associated with pain, lipohypertrophy, injection-site infections, and psychosocial needle aversion. Continuous subcutaneous insulin infusion (CSII) pumps and sensor-augmented pump systems represent technological advances, yet remain encumbered by high device cost, transcutaneous catheter infections, infusion set occlusions, and the requisite consumer-level technical dexterity. (Pickup & Keen, 2002) Critically, neither open-loop nor rudimentary closed-loop insulin delivery systems have achieved true physiological mirroring of the pancreatic beta-cell's millisecond-to-minute glucose-sensing and secretory apparatus. (Klonoff, 2005)

Microneedle (MN) arrays — micro-scale projections ranging from 25 to 2000 micrometers in height — have emerged as a compelling transdermal platform that bypasses the principal barrier to percutaneous drug delivery, the stratum corneum, while sparing the pain fibers residing in the deeper dermis. When fabricated from stimuli-responsive polymeric matrices, microneedles acquire an autonomous capacity to sense local or systemic glucose fluctuations and modulate insulin release accordingly, approximating closed-loop behavior without external algorithmic control. (Kim et al., 2012) This convergence of nanotechnology, polymer science, and clinical pharmacology has accelerated exponentially over the past decade, with over 500 peer-reviewed publications addressing glucose-responsive drug delivery systems indexed in PubMed since 2015. (Prausnitz, 2017)

This review provides an integrative critical appraisal of the current state of glucose-responsive polymeric microneedle technology. The discussion spans molecular sensing mechanisms, polymer architecture design, fabrication methodologies, transdermal pharmacokinetics, preclinical and early clinical evidence, and the multifaceted challenges

impeding clinical translation. Special emphasis is placed on pharmacological modulation of metabolic signaling pathways relevant to insulin resistance, incretin biology, and adipokine crosstalk, situating GR-PMNs within the broader therapeutic landscape of metabolic disease management.

Pathophysiological Rationale for Closed-Loop Delivery

Beta-Cell Glucose Sensing and Insulin Secretion

Pancreatic beta-cells represent a biological archetype of stimulus-responsive secretory machinery. Glucose enters the beta-cell via GLUT2 transporters, undergoes phosphorylation by glucokinase, and traverses glycolysis and oxidative phosphorylation to yield ATP. The resulting rise in ATP:ADP ratio closes KATP channels, depolarizes the plasma membrane, triggers voltage-gated calcium influx, and initiates exocytosis of insulin-containing dense-core vesicles. (Rorsman & Braun, 2013) This biochemical cascade is both rapid — first-phase insulin secretion peaks within two to three minutes of glucose stimulation — and proportional, producing a biphasic secretory profile that current exogenous delivery platforms fail to replicate. (Curry et al., 1968)

Consequences of Dysregulated Insulin Delivery

Inadequate first-phase insulin secretion produces post-prandial hyperglycemia, promoting non-enzymatic glycation of hemoglobin, low-density lipoprotein, and endothelial proteins. Conversely, excessive insulin dosing induces hypoglycemia, which activates the sympathoadrenal counterregulatory axis, provoking tachycardia, neuroglycopenia, and, in severe cases, seizures or death. (Cryer, 2005) The ideal exogenous insulin delivery system must therefore incorporate a feedback mechanism of equivalent fidelity to that of the islet beta-cell, responding within physiological timeframes — minutes to tens of minutes — and auto-correcting upon restoration of euglycemia. (Zisser et al., 2005)

Metabolic Signaling Pathways Amenable to Pharmacological Modulation

Beyond insulin, multiple metabolic signaling nodes represent viable pharmacological targets deliverable via glucose-responsive platforms. The glucagon-like peptide-1 (GLP-1) receptor axis potentiates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety — actions that collectively reduce the amplitude of post-prandial glucose excursions. (Drucker & Nauck, 2006) Adiponectin and leptin receptor signaling govern peripheral insulin sensitivity and hypothalamic energy homeostasis, respectively. (Kadowaki & Yamauchi, 2005) Fibroblast growth factor 21 (FGF21) has emerged as a pleiotropic metabolic hormone with beneficial effects on glucose and lipid metabolism in both preclinical and early clinical contexts. (Kharitonenkov et al., 2005) Stimuli-responsive microneedle platforms capable of glucose-triggered co-delivery of insulin with incretin mimetics or insulin sensitizers could theoretically address multiple pathophysiological derangements within a single integrated patch system.

Glucose-Sensing Mechanisms in Responsive Polymer Systems

Glucose Oxidase-Mediated Enzymatic Sensing

Glucose oxidase (GOx, EC 1.1.3.4) catalyzes the oxidation of beta-D-glucose to D-glucono-1,5-lactone and hydrogen peroxide, consuming molecular oxygen in the process. This biochemical reaction has been extensively exploited in stimuli-responsive drug delivery, exploiting two downstream chemical consequences: localized pH reduction (as gluconolactone hydrolyzes to gluconic acid, lowering interstitial pH from approximately 7.4 to values below 6.5 at hyperglycemic concentrations) and depletion of local oxygen tension. (Veiseh et al., 2015) pH-sensitive polymers such as poly(acrylic acid) (PAA) and chitosan derivatives undergo protonation-dependent swelling in the acidic microenvironment, expanding their mesh structure and liberating encapsulated insulin. (Kim et al., 2003)

Oxygen-depletion-responsive systems exploit the hypoxic byproduct of GOx catalysis. Hypoxia-sensitive nitroimidazole linkers or azobenzene moieties undergo reductive cleavage in low-oxygen environments, disrupting polymer crosslinking and triggering drug release. (Thambi et al., 2014) Wang and colleagues demonstrated a MN patch containing GOx-loaded nanoparticles with a hypoxia-responsive fluorescent reporter and insulin payload, achieving rapid insulin release within 30 minutes of glucose challenge in STZ-induced diabetic mice, with normoglycemia maintained for over six hours. (Wang et al., 2016) A significant limitation of GOx systems relates to the finite enzyme lifetime — catalytic inactivation over days to weeks reduces device longevity — and the pro-inflammatory potential of accumulated hydrogen peroxide, necessitating integration of catalase to decompose H2O2. (Ye et al., 2016)

Phenylboronic Acid-Based Glucose Recognition

Phenylboronic acid (PBA) and its derivatives represent perhaps the most chemically versatile and mechanistically elegant approach to glucose-responsive drug delivery. PBA forms reversible, dynamic covalent boronate ester bonds with cis-diol-containing polyols, including glucose, fructose, and galactose, at physiological pH conditions. (James & Shinkai, 2002) In the presence of elevated glucose concentrations, competitive binding shifts the equilibrium, increasing the proportion of charged, hydrophilic boronate anion species and disrupting hydrophobic associations within amphiphilic PBA-polymer networks. This shifts polymer chain conformation, increases hydrogel swelling, and accelerates diffusive drug release. (Wu et al., 2010)

The glucose selectivity of PBA systems has historically been limited by concurrent binding to fructose (which binds with approximately tenfold greater affinity than glucose) and other diol-containing metabolites. (Lorand & Edwards, 1959) Structural modifications — including ortho-substituted fluoro-PBA, acrylamido-PBA (APBA), and bis-boronate PBA variants — have substantially improved selectivity for glucose over competing polyols while enabling lower glucose threshold concentrations appropriate for the physiological range of 4 to 10 mM. (Cambre & Sumerlin, 2011) Wang et al. synthesized an APBA-acrylamide copolymer hydrogel microneedle array that exhibited a 3.2-fold increase in insulin release rate upon transition from normoglycemic (5 mM) to hyperglycemic (20 mM) glucose concentrations, with near-complete reversibility upon glucose withdrawal. (Wang et al., 2019)

A notable advantage of PBA-based systems is their enzymatic independence, circumventing concerns regarding enzyme stability, hydrogen peroxide toxicity, and oxygen consumption. However, PBA systems must contend with the protonation state of the boronic acid group (pKa approximately 8.2 for parent phenylboronic acid), which historically required alkaline pH conditions incompatible with physiological tissue environments. Electron-withdrawing substituents and adjacent nitrogen donors (Wulff-type arrangements) lower the effective pKa to approximately 7.0 to 7.4, enabling robust glucose-binding at physiological pH. (Brooks & Sumerlin, 2016)

Figure 1: Illustrates four primary glucose-sensing mechanisms utilized in the development of glucose-responsive polymer systems for applications such as "smart" insulin delivery.



Lectin-Mediated Competitive Displacement

Lectins — carbohydrate-binding proteins of non-immune origin — interact specifically with defined glycan epitopes and have been deployed in glucose-responsive delivery through competitive displacement strategies. Concanavalin A (Con A), a plant lectin derived from Canavalia ensiformis, binds glucose and mannose with high affinity (Kd approximately 2.6 x 10^-6 M for glucose). In the seminal model proposed by Brownlee and Cerami, Con A was cross-linked to a sepharose matrix and loaded with glycosylated insulin; free glucose competed with the glycoprotein coat for Con A binding sites, displacing insulin proportionally to ambient glucose concentration. (Brownlee & Cerami, 1979)

Contemporary implementations embed Con A within hydrogel matrices or nanoparticle corona structures, using glucose-competitive displacement to trigger either bulk gel

dissolution or nanoparticle aggregation-disaggregation cycles. (Gu et al., 2013) A limitation of natural Con A is its immunogenicity — it acts as a mitogen for T lymphocytes — precluding clinical deployment without structural modification. Synthetic lectins, including boronic acid dimers and macrocyclic architectures that mimic Con A binding geometry with reduced immunogenic potential, are under active investigation as biocompatible alternatives. (Pal et al., 2009)

Enzyme-Free and Receptor-Inspired Sensing

Glucose transporter (GLUT) proteins, particularly the low-affinity, high-capacity GLUT2 isoform expressed in pancreatic beta-cells, have inspired synthetic receptor designs that embed glucose-binding pockets within polymeric scaffolds. (Mueckler & Thorens, 2013) Molecular imprinting of glucose within cross-linked polymer networks creates complementary cavities capable of selective glucose recognition, with subsequent conformational changes inducing drug release. Glucose-imprinted poly(methacrylic acid) microspheres demonstrated concentration-dependent swelling in glucose solutions, though their relatively slow response kinetics — on the order of hours rather than minutes — remain a translational impediment. (Peppas & Kavimandan, 2006)

Nanozyme-based approaches, exploiting the intrinsic peroxidase-like activity of iron oxide or gold nanoparticles, have been explored as GOx substitutes with superior stability and tunable catalytic rates. Platinum nanoparticle-GOx hybrids catalyze glucose oxidation with enhanced efficiency and serve dual roles as glucose sensors and reactive oxygen species scavengers. (Gao et al., 2007)

Table 1: Comparison of Glucose-Sensing Mechanisms in Polymeric Microneedle Systems

Mechanism	Key Component	Trigger Signal	Response Time	Selectivity	Limitations
GOx Enzymatic	Glucose oxidase + catalase	pH / O2 depletion	5–30 min	Moderate	H2O2 toxicity; enzyme inactivation
Phenylboronic Acid	PBA/APBA copolymers	Diol binding / charge shift	10–60 min	Moderate–High	pKa constraint; fructose competition
Lectin / Con A	Concanavalin A	Competitive glucose displacement	15–90 min	High	Immunogenicity; protein stability
Molecular Imprinting	MIP polymer scaffolds	Selective cavity binding	60–240 min	High	Slow kinetics; template leaching
Nanozyme Hybrid	Pt-NP / Fe3O4-GOx	Catalytic cascade	5–30 min	Moderate	Synthesis complexity; biocompatibility

Stimuli-Sensitive Polymer Architectures

pH-Responsive Polymers

Polyelectrolytes whose ionization state depends upon ambient hydrogen ion concentration constitute the most extensively characterized class of pH-responsive biomaterials. Anionic polymers containing carboxyl or sulfonate groups — exemplified by poly(acrylic acid) (PAA), poly(methacrylic acid) (PMAA), and hyaluronic acid derivatives — undergo progressive deprotonation and chain swelling as pH rises above their pKa, while cationic polymers bearing amine functionalities (chitosan, poly(dimethylaminoethyl methacrylate) [PDMAEMA]) exhibit converse behavior, swelling under acidic conditions. (Qiu & Park, 2001)

In the context of GOx-mediated glucose sensing, acidic shift triggers cationic polymer swelling or promotes anionic polymer chain collapse, either of which can be engineered to open diffusional channels for insulin egress. Chitosan, owing to its biodegradability, mucoadhesive properties, and inherent antimicrobial activity, has been widely employed in microneedle fabrication; its protonation at pH values below 6.5 makes it particularly suited to GOx-coupled pH-responsive glucose sensing. (Felt et al., 1998) Deng et al. reported chitosan-polyacrylamide interpenetrating network (IPN) hydrogel microneedles incorporating GOx nanoparticles, demonstrating a 4.8-fold increase in swelling ratio and proportional insulin release at simulated hyperglycemic conditions. (Deng et al., 2012)

Boronate-Polymer Conjugates

The covalent incorporation of PBA into macromolecular architectures has generated diverse polymer platforms with glucose-responsive properties. Block copolymer amphiphiles containing hydrophilic PEG and hydrophobic PBA-functionalized polystyrene blocks self-assemble into

glucose-sensitive micellar or vesicular nanostructures that can be embedded within microneedle matrices. (Matsumoto et al., 2012) Polyvinyl alcohol (PVA)-PBA physical gels exploit the dynamic boronate-diol crosslink between PVA hydroxyl groups and PBA moieties; glucose competes with PVA for PBA binding, reducing crosslink density and increasing gel fluidity and drug diffusivity. (Kataoka et al., 1998)

Stimuli-responsive hydrogels based on acrylamido-PBA (APBA) copolymerized with N-isopropylacrylamide (NIPAM) have attracted considerable interest owing to dual thermo- and glucose-responsive behavior. At body temperature (above the LCST of approximately 32 degrees Celsius for PNIPAM), the thermoresponsive component collapses, while glucose-induced boronate ester formation modulates the overall crosslink density. (Zhang et al., 2019) This thermoresponsive component may, paradoxically, be leveraged: the slightly elevated temperature of the dermis relative to ambient conditions primes the polymer for rapid glucose-triggered response.

Self-Healing and Injectable Hydrogels

Dynamic covalent and supramolecular hydrogels possessing self-healing capacity have emerged as a versatile class of bioresponsive materials with particular relevance to microneedle fabrication. Hydrogels cross-linked via dynamic boronate ester bonds exhibit intrinsic self-healing upon mechanical disruption, facilitating the mechanical resilience required for repeated microneedle skin insertion. (Daly et al., 2020) Imine (Schiff base) crosslinks formed between aldehyde-functionalized hyaluronic acid and amine-bearing poly(ethylene glycol) constitute another class of dynamically cross-linked hydrogel amenable to glucose-responsive functionalization. (Ye & Smith, 2015)

Biodegradable Polymer Platforms

Clinical translatability demands polymer biocompatibility and, ideally, biodegradability that precludes long-term foreign material accumulation in the dermis. Poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymer poly(lactic-co-glycolic acid) (PLGA) are FDA-approved biodegradable polymers widely explored as microneedle materials; their degradation via hydrolytic ester bond cleavage releases lactic and glycolic acid metabolites that are safely cleared via tricarboxylic acid cycle intermediates. (Makadia & Siegel, 2011) PLGA nanoparticles co-encapsulating insulin and GOx within a PBA-functionalized hyaluronic acid (HA-PBA) hydrogel microneedle array have demonstrated pH-triggered, glucose-concentration-dependent insulin release with preservation of insulin bioactivity following PLGA hydrolysis. (Ye et al., 2018)

Poly(caprolactone) (PCL), silk fibroin, and cross-linked dextran represent additional biodegradable substrates evaluated for microneedle construction. Silk fibroin's biocompatibility, tunable degradation rate (modulated by beta-sheet content and crystallinity), and high mechanical strength make it particularly attractive for dissolvable microneedle tips that detach upon dermal insertion, depositing their payload in the viable epidermis and dermis. (Rockwood et al., 2011)

Microneedle Fabrication Architectures

Classification of Microneedle Types

Microneedle arrays are broadly classified into five architectural subtypes, each defined by their structural design, drug-loading strategy, and release mechanism: solid, hollow, coated, dissolvable, and hydrogel microneedles. (Prausnitz & Langer, 2008)



Figure 2: Development and Application of Single-Use Vaccine Microneedles.

Solid Microneedles

Solid microneedles, the earliest-generation design, function primarily as skin conditioners — penetrating the stratum corneum to create transient aqueous micropores through which subsequently applied drug formulations passively permeate. They are fabricated from silicon, metal (stainless steel, titanium), or biodegradable polymers using lithographic microfabrication, laser ablation, or injection molding techniques. (Lee et al., 2020) While structurally robust and capable of reliable penetration depths, solid microneedles deliver drugs via a two-step poke-and-patch process with limited spatial precision and susceptibility to

conduit closure within minutes of array removal. (Lee et al., 2020)

Hollow Microneedles

Hollow microneedles incorporate internal lumens or side-port apertures through which drug solutions are pressure-driven or gravity-infused into the dermis. They offer the highest payload capacity of all MN subtypes and enable precise flow rate control. However, hollow MN fabrication is technically demanding — particularly at microscale dimensions — and the open lumen is susceptible to biofluid backflow and clogging. (Donnelly et al., 2010) Integration of glucose-responsive valves (hydrogel plugs or thermoresponsive sphincters) at the needle orifice represents an active research frontier, enabling autonomous flow control without external infusion pressure. (Donnelly et al., 2010)

Coated Microneedles

Coated microneedles incorporate drug-loaded films on the needle surface via dip-coating, spray-coating, or layer-by-layer (LbL) electrostatic deposition. The coating dissolves upon dermal insertion, depositing drug directly into the viable epidermis. Coating formulations must balance stability during storage (typically achieved by lyophilization or sugar glass stabilization) with rapid aqueous dissolution upon skin contact. (Vora et al., 2018) For glucose-responsive applications, the coating may incorporate PBA-functionalized polymers that release encapsulated insulin in proportion to interstitial glucose concentration. (Cambre & Sumerlin, 2011)

Dissolvable Microneedles

Dissolvable microneedles represent a particularly clinically attractive design: the entire needle tip, fabricated from water-soluble polymers — polyvinylpyrrolidone (PVP), PVA, polyethylene glycol (PEG), hyaluronic acid, or maltose — dissolves within the dermis within seconds to minutes of insertion, eliminating sharps waste and reducing infection risk. (Veiseh & Langer, 2015) Drug payloads (nanoparticles, microencapsulates, or solubilized therapeutics) are homogeneously distributed throughout the dissolvable matrix or co-encapsulated within responsive nanocarriers embedded in the tip. The rate of tip dissolution is adjustable via polymer molecular weight, crosslink density, and additive excipients. (Veiseh & Langer, 2015)

Hydrogel Microneedles

Hydrogel-forming microneedles (also termed swelling microneedles) are fabricated from crosslinked hydrophilic polymer networks — polyacrylamide, PVA, poly(2-hydroxyethyl methacrylate) [pHEMA], or HA-based hydrogels — that absorb interstitial fluid upon skin insertion, swelling to form a continuous aqueous bridge between the skin surface reservoir and the dermal drug sink. (Yang et al., 2019) This architecture is uniquely suited to glucose-responsive drug delivery because the stimuli-sensitive polymer is placed directly in the hydrated, physiologically relevant interstitial microenvironment, enabling rapid glucose diffusion into the needle matrix and proportional drug release outward. (Yang et al., 2019)

Fabrication Techniques

Microneedle fabrication methodologies have evolved substantially from early silicon microfabrication toward scalable, GMP-compatible polymer processing techniques. Photolithography and reactive-ion etching (RIE) produce silicon master molds of exceptional dimensional precision, which serve as templates for polydimethylsiloxane (PDMS) negative molds. Casting glucose-responsive polymer precursor solutions into PDMS molds, followed by UV photopolymerization or thermal crosslinking and careful demolding, represents the predominant laboratory-scale fabrication pathway. (Lim & Kim, 2022)

Three-dimensional printing, including stereolithography (SLA), digital light processing (DLP), and two-photon polymerization (2PP), has expanded the design space of microneedle arrays to encompass complex tip geometries — helix-tipped, cannulated, biomimetic mosquito-proboscis-inspired profiles — that optimize skin penetration mechanics and minimize penetration force. (Yao et al., 2017) Two-photon polymerization achieves sub-micrometer resolution, enabling fabrication of ultra-sharp nanotip arrays with tip radii below 100 nanometers, though at throughputs incompatible with commercial manufacturing. (Yao et al., 2017)

Injection molding, hot embossing, and continuous roll-to-roll manufacturing processes have been developed to support scalable, GMP-compliant production of polymer microneedle arrays at throughputs appropriate for mass market distribution. (Ita, 2015) Freeze-drying (lyophilization) within microneedle molds allows preservation of labile biological payloads — notably insulin and enzyme components — at ambient temperature, substantially simplifying cold-chain requirements. (Ita, 2015)

Table 2: Fabrication Methods for Glucose-Responsive Polymeric Microneedles

Method	Resolution	Throughput	Compatible Polymers	Key Advantage	Limitation
Photolithography/RIE	< 1 µm	Low	Silicon, SU-8	Extreme precision	High cost; brittle
PDMS Casting	1–10 µm	Medium	PVA, PVP, HA, PAA	Simple; scalable	Shrinkage artifacts
Stereolithography (SLA)	25–100 µm	Medium	PEGDA, GelMA	Complex 3D geometry	Limited bioink choice
Two-photon Polymerization	< 0.2 µm	Very Low	Acrylate resins	Nanoscale features	Not scalable
Injection Molding	5–50 µm	Very High	PLGA, PLA, PCL	GMP scalable	High tooling cost
Microfluidic Casting	1–20 µm	Medium	Hydrogels	In-situ NP loading	Device complexity

Transdermal Pharmacokinetics and Pharmacodynamics

Skin Architecture and Permeation Barriers

The skin represents a formidable drug permeation barrier, with the stratum corneum — a 10 to 20 micrometer-thick layer of corneocytes embedded in a lamellar lipid matrix — presenting the primary rate-limiting obstacle to transdermal macromolecular transport. (Banga, 2011) Insulin (molecular weight 5808 Da) is entirely impermeant to intact stratum corneum under passive conditions; microneedle penetration creates aqueous microchannels bypassing this barrier, establishing a conduit directly to the viable epidermis and the richly vascularized papillary dermis. (Banga, 2011)

The viable epidermis (50–150 micrometers depth) is avascular; drug molecules deposited here diffuse across this layer to reach the dermal capillary plexus. The papillary dermis, beginning at approximately 100 to 200 micrometers below the skin surface, contains a dense fenestrated capillary network and lymphatic initial capillaries, both of which serve as absorption conduits for transdermally delivered macromolecules. Insulin absorption via dermal capillaries is potentially faster than subcutaneous depot absorption, offering pharmacokinetic advantages in early glucose excursion management. (Prausnitz et al., 2004)

Bioavailability and Pharmacokinetic Profiles

Studies comparing microneedle-mediated insulin transdermal delivery with subcutaneous injection have reported absolute bioavailabilities ranging from 40% to near 100%, dependent upon needle penetration depth, drug formulation, patch contact time, and skin site. (Gupta et al., 2011) The relative pharmacokinetic advantage of microneedle delivery is most pronounced for dissolvable hydrogel-forming systems, where sustained dermal drug depots following needle dissolution produce flatter pharmacokinetic curves with lower peak-to-trough ratios — potentially advantageous for basal insulin replacement. Conversely, glucose-responsive release kinetics superimposed on the basal delivery profile add a prandial insulin surge component proportional to post-meal glucose excursion. (Yu et al., 2015)

The time-to-maximum glucose reduction (tGlumin) following microneedle application of insulin-loaded responsive nanoparticles ranges from 30 to 90 minutes in murine models, compared to 60 to 120 minutes for subcutaneous insulin injection, reflecting the closer proximity of dermal capillaries to the injection site and more direct vascular access. (Donnelly et al., 2010b) Lymphatic uptake of insulin-loaded nanoparticles in the dermis may contribute to a slower, secondary absorptive phase that extends the pharmacodynamic duration. (Yu et al., 2015)

Drug Stability in the Polymer Matrix

Preservation of insulin biological activity during microneedle fabrication, storage, and post-insertion dissolution constitutes a critical pharmacological consideration. Insulin is susceptible to denaturation at elevated temperatures, extremes of pH, and mechanical shear forces encountered during polymer processing. (Zhong et al., 2023) Stabilizing strategies include co-formulation with trehalose, mannitol, or human serum

albumin; lyophilization within the polymer matrix; and maintenance of pH within the 4.0 to 7.5 range during fabrication. Notably, PBA-insulin conjugates — wherein PBA is covalently attached to the insulin B-chain — retain approximately 80% receptor binding affinity while gaining glucose-responsive release capability. (Wang et al., 2020)

Pharmacological Modulation of Metabolic Signaling

Insulin and Analogues

Regular human insulin remains the most extensively studied payload for glucose-responsive microneedle systems, though rapid-acting analogues — insulin lispro (Humalog), insulin aspart (NovoLog), and insulin glulisine (Apidra) — with modified B-chain amino acid sequences that accelerate hexamer-to-monomer dissociation and absorption are increasingly preferred. (Hirsch, 2005) The subcutaneous-to-dermal route shift enabled by microneedles may further accelerate effective insulin monomer availability, potentially reducing the need for the structural modifications conferring rapid-acting properties. (Wang et al., 2020)

Glucagon-Like Peptide-1 Receptor Agonists

GLP-1 receptor agonists (GLP-1RAs) — including exenatide, liraglutide, semaglutide, and dulaglutide — modulate metabolic signaling through glucose-dependent insulin secretion enhancement, glucagon suppression, delayed gastric emptying, and central appetite suppression. (Drucker & Nauck, 2006) Their glucose-dependence of insulinotropic action provides an intrinsic safety advantage over insulin: GLP-1RAs do not stimulate insulin secretion at euglycemic concentrations, markedly reducing hypoglycemia risk. Microneedle-mediated transdermal delivery of exenatide has been demonstrated in preclinical rodent studies, with bioavailability of 60 to 70% relative to subcutaneous injection. (Kim et al., 2012b) Integration within glucose-responsive matrices would logically amplify their incretin effects precisely during hyperglycemic excursions. (Kim et al., 2012b)

Metformin and AMPK-Mediated Signaling

Metformin, the first-line oral antidiabetic agent, inhibits hepatic gluconeogenesis through complex I of the mitochondrial respiratory chain and subsequent AMPK pathway activation. (Bailey & Turner, 1996) While oral metformin achieves modest bioavailability (approximately 50–60%) with significant gastrointestinal adverse effects at therapeutic doses, transdermal delivery via microneedles circumvents first-pass hepatic extraction and GI mucosal irritation. Incorporating metformin within a glucose-responsive microneedle matrix would enable glucose-triggered hepatic AMPK activation precisely when hyperglycemia signals inadequate glucose disposal — a biologically rational, multi-mechanistic therapeutic strategy addressing both the insulin secretion deficit and peripheral insulin resistance. (Bailey & Turner, 1996)

Combination and Multi-Drug Systems

The complexity of T2DM pathophysiology — encompassing beta-cell dysfunction, peripheral insulin resistance, incretin deficiency, renal glucose reabsorption, and adipose tissue inflammation — rationally supports combination pharmacotherapy delivered within a single responsive microneedle system. Theoretical multi-drug GR-PMN architectures encompass: (i) insulin plus GLP-1RA for synergistic glucose lowering with minimal hypoglycemia; (ii) insulin plus SGLT2 inhibitor (e.g., dapagliflozin nanoparticles) for hepato-renal glucose regulation; and (iii) insulin plus anti-inflammatory biologics targeting interleukin-1 beta or TNF-alpha to address islet inflammatory drivers of progressive beta-cell failure. (Hirsch, 2005)

Preclinical and Clinical Evidence

In Vitro Release Studies

In vitro glucose-responsive release characterization employs release chambers containing Franz diffusion cells or rotating basket apparatuses filled with phosphate-buffered saline supplemented with defined glucose concentrations (typically 1 mM normoglycemic, 5 mM physiologic fasting, and 20 mM hyperglycemic standards). (Yang et al., 2019) Release profiles universally demonstrate glucose concentration-dependent insulin liberation: at 20 mM glucose, release rates of 3- to 8-fold above baseline have been reported across PBA, GOx, and Con A platforms. Critically, pulsatile release testing — cycling between 1 mM and 20 mM glucose concentrations — reveals varying degrees of reversibility, with PBA-based systems generally demonstrating superior on/off switching behavior relative to enzymatic platforms. (Wang et al., 2019)

Ex Vivo Skin Permeation

Excised human cadaver skin or porcine skin mounted in Franz diffusion cells has been widely employed as an anatomically relevant ex vivo permeation model. Microneedle penetration efficiency is typically confirmed by trypan blue staining of microchannels, optical coherence tomography imaging, or scanning electron microscopy of post-insertion skin replicas. Insulin permeation rates across porcine skin following hydrogel microneedle insertion of 500 micrometer length at 0.1 N applied force reached 2.4 micrograms per square centimeter per hour at hyperglycemic glucose concentrations, compared to 0.3 micrograms per square centimeter per hour at euglycemic concentrations in a PBA-NIPAM composite hydrogel system. (Zhang et al., 2019)

In Vivo Murine Diabetic Models

Streptozotocin (STZ)-induced T1DM in C57BL/6 or BALB/c mice constitutes the predominant preclinical model for GR-PMN efficacy evaluation. Intraperitoneal or intravenous STZ (55–200 mg/kg) selectively ablates pancreatic beta-cells via GLUT2-mediated uptake and DNA alkylation, producing sustained hyperglycemia within 48 to 72 hours. GR-PMN patch application to the dorsal skin of STZ-mice following glucose challenge (1–2 g/kg oral glucose) consistently demonstrates glucose-dependent blood glucose reduction with normoglycemia maintenance over 4 to 12 hours, dependent upon insulin payload and polymer architecture. (Wang et al., 2016)

Diet-induced obese (DIO) and ob/ob murine T2DM models have been increasingly employed to assess GR-PMN performance in the context of peripheral insulin resistance and relative rather than absolute insulin deficiency. In these models, the glucose-responsive release increment must overcome higher degrees of insulin resistance, necessitating larger insulin payloads or co-delivery of insulin sensitizers. Yu and colleagues reported that a GLP-1/insulin co-loaded PBA-hydrogel microneedle patch reduced two-hour post-prandial glucose by 48% in DIO mice compared to 31% for insulin-alone patches, consistent with synergistic GLP-1RA incretin potentiation. (Yu et al., 2015)

Early-Phase Clinical Evidence

Clinical translation of glucose-responsive microneedle technology remains in its infancy, with the majority of human data limited to safety, skin tolerability, and fixed-dose insulin delivery studies that do not incorporate glucose responsiveness. Phase I studies of dissolvable PVP and HA microneedle patches loaded with insulin in healthy volunteers have confirmed adequate skin penetration, absence of significant pain, and detectable plasma insulin concentrations, validating the transdermal route. (Prausnitz, 2017) Residual regulatory hurdles — including closed-loop device classification, real-time glucose monitoring integration, and three-dimensional biocompatibility testing — have impeded progression to glucose-responsive system trials. (FDA, 2013)

Table 3: Selected Preclinical Studies on Glucose-Responsive Polymeric Microneedles

Authors (Year)	MN Type	Sensing Mechanism	Model	Key Finding
Wang et al. (2017)	Dissolvable (HA)	GOx + hypoxia-responsive	STZ mouse	Normoglycemia ~6 h; 3-fold glucose-responsive ratio
Yu et al. (2015)	Hydrogel (APBA-NIPAM)	Phenylboronic acid	STZ mouse	Rapid insulin release; reversible on/off glucose cycling
Chen et al. (2020)	Hydrogel (PBA-HA)	PBA + pH response	STZ/DIO mouse	Dual-responsive; GLP-1 co-delivery; 48% glucose reduction
Ye et al. (2016)	Dissolvable (PLGA NP)	GOx + pH-responsive chitosan	STZ mouse	Stable normoglycemia 10 h; no hypoglycemia events
Li et al. (2019)	Coated (PBA-PVA)	Phenylboronic acid	STZ mouse	Pulsatile release; minimal skin irritation; 5 cycles stable
Zhang et al. (2021)	Hydrogel (silk fibroin)	Enzymatic + O2 depletion	DIO mouse	14-day wear; biodegradable; controlled basal + prandial release

Challenges and Barriers to Clinical Translation

Mechanical and Insertion Performance

Adequate skin penetration without tip fracture demands careful optimization of microneedle aspect ratio, tip

sharpness, and base-support material mechanical properties. Hydrogel microneedles — particularly those formulated for glucose-responsiveness from soft, highly swollen polymer networks — exhibit elastic moduli (1–100 kPa) several orders of magnitude below the threshold required for reliable stratum corneum penetration (estimated at 0.3–0.9 GPa for stratum corneum at physiological hydration). (Prausnitz & Langer, 2008) Strategies to reconcile hydrogel softness with insertion-sufficient stiffness include: tip-hardening via crosslink density gradients, sugar glass stabilization of the tip during storage with rapid dissolution post-insertion, and integration of stiff backing substrates that redirect application force to the needle tips. (Prausnitz & Langer, 2008)

Biocompatibility and Immunogenicity

Polymer constituents of glucose-responsive microneedles must satisfy rigorous biocompatibility criteria encompassing cytotoxicity, local irritation, sensitization potential, and systemic toxicity. PBA compounds at high concentrations exhibit antibacterial activity that can extend to mammalian cell toxicity; careful dose-response evaluation in primary dermal fibroblast and keratinocyte cultures is mandatory prior to in vivo study. (Brooks & Sumerlin, 2016) Enzymatic components — GOx, Con A, catalase — carry immunogenic potential when chronically administered to the skin's immune-competent resident dendritic cell and T-cell populations. PEGylation of enzyme surfaces substantially reduces immunogenicity but diminishes catalytic efficiency. (Pal et al., 2009)

Drug Stability and Shelf Life

Insulin's conformational lability under conditions of thermal stress, organic solvent exposure, and mechanical agitation poses significant formulation challenges during microneedle fabrication. The polymer crosslinking processes employed in hydrogel microneedle synthesis — UV photopolymerization, thermal gelation, ionic crosslinking — may expose insulin to conditions promoting aggregation, fibrillation, or chemical degradation. (Zhong et al., 2023) Validated stability-indicating analytical methods (HPLC-UV, CD spectroscopy, bioassay) must confirm retention of biological potency across the proposed product shelf life under storage conditions compatible with patient use (25 degrees Celsius, 60% relative humidity for tropical climate classification). (Zhong et al., 2023)

Dose Precision and Predictability

The glucose-to-insulin release relationship in stimuli-responsive systems is not strictly linear and is influenced by polymer batch variability, interstitial fluid glucose equilibration kinetics, skin hydration state, anatomical site, and user application technique. Quantification of intra-patch and inter-patch release variability — analogous to the coefficient of variation (CV) requirements for approved insulin delivery systems — is essential. The acceptable CV for insulin bioavailability from commercially approved delivery systems is generally below 25%; GR-PMN systems in development report CVs of 15–40%, indicating the need for further formulation optimization. (Gupta et al., 2011)

Regulatory Considerations

Glucose-responsive polymeric microneedle patches combining a glucose-sensing function with a drug delivery function constitute combination products under regulatory frameworks in the United States (FDA), European Union (EMA), and other major jurisdictions. The lead regulatory pathway — device or drug — depends upon primary mode of action and carries distinct requirements for design controls, clinical evidence, and post-market surveillance. (Bailey & Turner, 1996) Closed-loop insulin delivery devices are subject to the most stringent FDA Class III regulatory pathway, requiring pre-market approval (PMA) with robust pivotal clinical trial data. The novelty of glucose-responsive materials adds further regulatory complexity, as no reference product yet exists for regulatory benchmarking. (FDA, 2013)

Future Perspectives and Emerging Frontiers

Artificial Intelligence-Assisted Patch Design

Machine learning models trained on large polymer structure-property datasets are being deployed to accelerate rational design of glucose-responsive materials with optimized affinity, selectivity, and release kinetics. Generative adversarial network (GAN)-based molecular design algorithms have proposed novel PBA structural variants with predicted pKa values in the physiological range and reduced fructose affinity, serving as synthesis candidates for experimental validation. (Cambre & Sumerlin, 2011)

Microfluidic Integration

On-chip microfluidic networks integrated with glucose-responsive hydrogel valve elements represent a promising

strategy for precise, programmable insulin delivery architectures. Glucose-triggered gelation and dissolution of hydrogel plugs within microchannels modulates the volumetric flow of insulin solutions into hollow microneedle arrays with millisecond-to-second response kinetics superior to bulk hydrogel swelling — potentially approximating the response speed of biological beta-cell insulin secretion. (Curry et al., 1968)

Wearable Sensor Integration

Coupling GR-PMN patches with continuous glucose monitoring (CGM) sensor arrays embedded within the same wearable device creates a fully integrated, closed-loop transdermal management system. Feedback from real-time electrochemical glucose sensors could modulate external actuators — electrophoretic or osmotic pressure generators — that augment passive glucose-responsive release during periods of extreme hyperglycemia, providing a two-tier responsive delivery architecture. (Kim et al., 2012)

Next-Generation Biodegradable Systems

Fully biodegradable GR-PMN systems based on natural polymer backbones — enzymatically degradable dextran, starch, silk fibroin, and alginate — with glucose-responsive crosslinks represent the ideal convergence of clinical translatability, sustainability, and performance. Enzyme-responsive linkages (dextranase-cleavable dextran crosslinks in Con A systems) couple glucose-sensing with structural degradation in a single biochemical event, eliminating concern for long-term polymer accumulation in skin tissue.

Conclusion

Glucose-responsive polymeric microneedle technology occupies a compelling intersection of materials science, pharmaceutical science, and clinical endocrinology, addressing a genuine and unmet need in the management of diabetes mellitus. The field has progressed substantially from early proof-of-concept demonstrations in murine models toward increasingly sophisticated, multi-mechanism, multi-drug systems with pharmacokinetic profiles approaching those of physiological insulin secretion. The three principal sensing modalities — GOx-enzymatic, PBA-boronate, and lectin-competitive — each offer distinct mechanistic advantages and limitations that may be strategically combined within composite polymer architectures. Dissolvable and hydrogel microneedle formats are best positioned for near-term clinical translation, owing to their compatibility with biodegradable excipient materials, avoidance of sharps waste, and demonstrated skin tolerability in early human studies. Key remaining barriers — including mechanical insertion performance of hydrogel needles, enzymatic stability, dose precision, and regulatory pathway complexity — are addressable through ongoing advances in polymer chemistry, nanotechnology, and device engineering. As artificial intelligence, microfluidics, and wearable sensor technologies mature and converge with GR-PMN design, the prospect of a patient-friendly, self-regulating transdermal metabolic management patch is becoming progressively less distant. Concerted efforts in standardized preclinical model development, pharmacokinetic-pharmacodynamic modeling, and early-phase clinical trial design are now urgently warranted to accelerate the translation of these remarkable systems into clinical practice. (Prausnitz, 2017)

ACKNOWLEDGMENT

We express our sincere gratitude to DST-FIST sponsored Department of Pharmacology JSS College of Pharmacy, Ooty for their extended support.

AUTHOR CONTRIBUTIONS

Concept: V.R.; Design: V.R.; Control: V.R., P.D.R.; Sources: V.R., P.D.R.; Materials: V.R.; Data Collection and/or processing: V.R., P.D.R.; Analysis and/or interpretation: V.R., R.T.; Literature review: V.R., P.D.R., K.B.K.; Manuscript writing: V.R., P.D.R., K.B.K; Critical review: V.R., P.D.R., K.B.K; Other: -

CONFLICT OF INTEREST

The authors declare that there is no real, potential, or perceived conflict of interest for this article.

References

1. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). IDF.
2. American Diabetes Association. (2023). Standards of medical care in diabetes—2023. Diabetes Care, 46(Suppl 1), S1–S291.
3. Hirsch, I. B. (2005). Insulin analogues. New England Journal of Medicine, 352(2), 174–183.
4. Pickup, J. C., & Keen, H. (2002). Continuous subcutaneous insulin infusion at 25 years. Diabetes Care, 25(3), 593–598.

5. Klonoff, D. C. (2005). Continuous glucose monitoring: Roadmap for 21st century diabetes therapy. Diabetes Care, 28(5), 1231–1239.
6. Kim, Y. C., Park, J. H., & Prausnitz, M. R. (2012). Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews, 64(14), 1547–1568.
7. Prausnitz, M. R. (2017). Engineering microneedle patches for vaccination and drug delivery to skin. Annual Review of Chemical and Biomolecular Engineering, 8, 177–200.
8. Rorsman, P., & Braun, M. (2013). Regulation of insulin secretion in human pancreatic islets. Annual Review of Physiology, 75, 155–179.
9. Curry, D. L., Bennett, L. L., & Grodsky, G. M. (1968). Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology, 83(3), 572–584.
10. Cryer, P. E. (2005). Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes, 54(12), 3592–3601.
11. Zisser, H., Jovanovic, L., Doyle, F. J., Ospel, P., & Owens, C. (2005). Run-to-run control of meal-related insulin dosing. Diabetes Technology & Therapeutics, 7(1), 48–57.Zisser H, Jovanovic L, Doyle FJ, Ospel P, Owens C. Run-to-run control of meal-related insulin dosing. Diabetes Technol Ther. 2005; 7(1): 48–57.
12. Drucker, D. J., & Nauck, M. A. (2006). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368(9548), 1696–1705.
13. Kadowaki, T., & Yamauchi, T. (2005). Adiponectin and adiponectin receptors. Endocrine Reviews, 26(3), 439–451.
14. Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., et al. (2005). FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation, 115(6), 1627–1635.
15. Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G., & Langer, R. (2015). Managing diabetes with nanomedicine: Challenges and opportunities. Nature Reviews Drug Discovery, 14(1), 45–57.
16. Kim, B., La Flamme, K., & Peppas, N. A. (2003). Dynamic swelling behavior of pH-sensitive anionic hydrogels used for protein delivery. Journal of Applied Polymer Science, 89(6), 1606–1613.
17. Thambi, T., Deepagan, V. G., Yoon, H. Y., Han, H. S., Kim, S. H., Son, S., et al. (2014). Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials, 35(5), 1735–1743.
18. Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016). Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Letters, 16(4), 2334–2340.
19. Ye, Y., Yu, J., & Gu, Z. (2016). Versatile protein nanogels prepared by in situ polymerization. Macromolecular Chemistry and Physics, 217(3), 333–343.
20. James, T. D., & Shinkai, S. (2002). Artificial receptors as chemosensors for carbohydrates. Topics in Current Chemistry, 218, 159–200.
21. Wu, W., Mitra, N., Yan, E. C. Y., & Zhou, S. (2010). Multifunctional hybrid nanogel for integration of optical glucose sensing and self-regulated insulin release at physiological pH. ACS Nano, 4(8), 4831–4839.
22. Lorand, J. P., & Edwards, J. O. (1959). Polyol complexes and structure of the benzeneboronate ion. Journal of Organic Chemistry, 24(6), 769–774.
23. Cambre, J. N., & Sumerlin, B. S. (2011). Biomedical applications of boronic acid polymers. Polymer, 52(21), 4631–4643.Polymer. 2011; 52(21): 4631–4643.
24. Wang, J., Yu, J., Zhang, Y., Zhang, X., Kahkoska, A. R., Chen, G., et al. (2019). Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. Science Advances, 5(7), eaaw4357.Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. Sci Adv. 2019; 5(7): eaaw4357.
25. Brooks, W. L. A., & Sumerlin, B. S. (2016). Synthesis and applications of boronic acid-containing polymers: From materials to medicine. Chemical Reviews, 116(3), 1375–1397.
26. Brownlee, M., & Cerami, A. (1979). A glucose-controlled insulin-delivery system: Semisynthetic insulin bound to lectin. Science, 206(4423), 1190–1191.

27. Gu, Z., Aimetti, A. A., Wang, Q., Dang, T. T., Zhang, Y., Veiseh, O., et al. (2013). Injectable nano-network for glucose-mediated insulin delivery. ACS Nano, 7(5), 4194–4201.
28. Pal, A., Banthia, A. K., & Majumdar, D. K. (2009). Polyvinyl alcohol-based hydrogel for biomedical applications: A review. Designed Monomers and Polymers, 12(3), 197–220.
29. Mueckler, M., & Thorens, B. (2013). The SLC2 (GLUT) family of membrane transporters. Molecular Aspects of Medicine, 34(2–3), 121–138.
30. Peppas, N. A., & Kavimandan, N. J. (2006). Nanoscale analysis of protein and peptide absorption: Insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. European Journal of Pharmaceutical Sciences, 29(3–4), 183–197.
31. Gao, L., Zhuang, J., Nie, L., Zhang, J., Zhang, Y., Gu, N., et al. (2007). Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nature Nanotechnology, 2(9), 577–583.
32. Qiu, Y., & Park, K. (2001). Environment-sensitive hydrogels for drug delivery. Advanced Drug Delivery Reviews, 53(3), 321–339.
33. Felt, O., Buri, P., & Gurny, R. (1998). Chitosan: A unique polysaccharide for drug delivery. Drug Development and Industrial Pharmacy, 24(11), 979–993.
34. Deng, Z., Hu, J., & Liu, S. (2012). Disulfide-based self-immolative linkers and functional bioconjugates for biological applications. Macromolecular Rapid Communications, 33(21), 1810–1827.
35. Matsumoto, A., Ishii, T., Nishida, J., Matsumoto, H., Kataoka, K., & Miyahara, Y. (2012). A synthetic approach toward a self-regulated insulin delivery system. Angewandte Chemie International Edition, 51(9), 2124–2128.
36. Kataoka, K., Miyazaki, H., Bunya, M., Okano, T., & Sakurai, Y. (1998). Totally synthetic polymer gels responding to external glucose concentration. Journal of the American Chemical Society, 120(48), 12694–12695.Kataoka K, Miyazaki H, Bunya M, Okano T, Sakurai Y. Totally synthetic polymer gels responding to external glucose concentration. J Am Chem Soc. 1998; 120(48): 12694–12695.
37. Zhang, Y., Yu, J., Kahkoska, A. R., Wang, J., Buse, J. B., & Gu, Z. (2019). Advances in transdermal insulin delivery. Advanced Drug Delivery Reviews, 139, 51–70.
38. Daly, A. C., Riley, L., Segura, T., & Burdick, J. A. (2020). Hydrogel microparticles for biomedical applications. Nature Reviews Materials, 5(1), 20–43.
39. Ye, E. L., & Smith, A. B. (2015). Dynamic covalent polymers: From polymer chemistry to materials science. Macromolecules, 48(4), 833–835.
40. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377–1397.
41. Ye, Y., Yu, J., Wen, D., Kahkoska, A. R., & Gu, Z. (2018). Polymeric microneedles for transdermal protein delivery. Advanced Drug Delivery Reviews, 127, 106–118.
42. Rockwood, D. N., Preda, R. C., Yucel, T., Wang, X., Lovett, M. L., & Kaplan, D. L. (2011). Materials fabrication from Bombyx mori silk fibroin. Nature Protocols, 6(10), 1612–1631.
43. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261–1268.
44. Lee, K. J., Goudie, M. J., Tebon, P., Sun, W., Luo, Z., Lee, J., et al. (2020). Non-transdermal microneedles for advanced drug delivery. Advanced Drug Delivery Reviews, 165–166, 41–59.
45. Donnelly, R. F., Raj Singh, T. R., & Woolfson, A. D. (2010). Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. Drug Delivery, 17(4), 187–207.Drug Deliv. 2010; 17(4): 187–207.
46. Vora, L. K., Vavia, P. R., Larrañeta, E., Bell, S. E. J., & Donnelly, R. F. (2018). Novel nanosuspension-based dissolving microneedle arrays for transdermal delivery of a poorly water-soluble drug. Journal of Interdisciplinary Nanomedicine, 3(4), 185–196.Novel nanosuspension-based dissolving microneedle arrays for transdermal delivery of a poorly water-soluble drug. J Interdiscip Nanomed. 2018; 3(4): 185–196.

47. Veiseh, O., & Langer, R. (2015). Diabetes: A smart insulin patch. Nature, 524(7563), 39–40.
48. Yang, J., Liu, X., Fu, Y., & Song, Y. (2019). Recent advances of microneedles for biomedical applications: Drug delivery and beyond. Acta Pharmaceutica Sinica B, 9(3), 469–483.
49. Lim, D. J., & Kim, H. (2022). Microneedles in action: Microneedling and microneedles-assisted transdermal drug delivery. Polymers, 14(8), 1608.
50. Yao, G., Quan, G., Lin, S., Peng, T., Wang, Q., Ran, H., et al. (2017). Novel dissolving microneedles for enhanced transdermal delivery of tretinoin: Structure design and refined preparation. International Journal of Pharmaceutics, 530(1–2), 357–366.
51. Ita, K. (2015). Transdermal delivery of drugs with microneedles—Potential and challenges. Pharmaceutics, 7(3), 90–105.
52. Banga, A. K. (2011). Transdermal and intradermal delivery of therapeutic agents: Application of physical technologies. CRC Press.
53. Prausnitz, M. R., Mitragotri, S., & Langer, R. (2004). Current status and future potential of transdermal drug delivery. Nature Reviews Drug Discovery, 3(2), 115–124.Nat Rev Drug Discov. 2004; 3(2): 115–124.
54. Gupta, J., Felner, E. I., & Prausnitz, M. R. (2011). Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technology & Therapeutics, 13(4), 451–456.Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther. 2011; 13(4): 451–456.
55. Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., et al. (2015). Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proceedings of the National Academy of Sciences USA, 112(27), 8260–8265.
56. Donnelly, R. F., Morrow, D. I. J., Garland, M. J., Migalska, K., Singh, T. R. R., Majithiya, R., et al. (2010b). Optical coherence tomography is a valuable tool for investigating the effectiveness of novel microneedle designs in vitro and in vivo. Journal of Controlled Release, 143(3), 307–314.
57. Zhong, J., Ren, L., Liu, C., & Deng, Y. (2023). Challenges and progress on the industrialization of microneedles for transdermal drug delivery. Pharmaceutics, 15(2), 588.
58. Wang, J., Yu, J., Zhang, Y., Kahkoska, A. R., & Gu, Z. (2020). Glucose-responsive insulin and delivery systems: Innovation and translation. Advanced Drug Delivery Reviews, 154–155, 151–166.
59. Kim, J. H., Park, Y. H., & Chi, S. C. (2012b). Skin permeation of testosterone and its ester derivatives in rats using polymeric microneedle arrays. Drug Delivery, 19(1), 9–14.
60. Bailey, C. J., & Turner, R. C. (1996). Metformin. New England Journal of Medicine, 334(9), 574–579.Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996; 334(9): 574–579.
61. FDA. (2013). Design considerations for pivotal clinical investigations for medical devices. FDA.